|Bid||4.2700 x 1000|
|Ask||4.3900 x 1000|
|Day's Range||4.3100 - 4.4700|
|52 Week Range||3.7800 - 9.2500|
|Beta (3Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 14, 2019 - Oct 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
GERMANTOWN, Md., Aug. 14, 2019 -- Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development.
Generates $1 Million in Sales through New POCare Platform Ends Quarter with Over $16 Million of Cash and Cash Equivalents GERMANTOWN, Md., Aug. 12, 2019 -- Orgenesis.
Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy, caused by chronic pancreatitis. Orgenesis has an exclusive license for the technology from Israel's Tel Hashomer Medical Research Infrastructure and Services Ltd., that is based on the work of Professor Sarah Ferber, the company's chief scientific officer and a researcher at THM. Patients who have total pancreatectomy always suffer from diabetes, which results in lifelong insulin-dependence with the loss of endogenous insulin secretion and that of the counter-regulatory hormone, glucagon. Shares have fallen 8% in 2019, while the S&P 500 has gained 15%.
GERMANTOWN, Md., June 17, 2019 -- Orgenesis Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a developer, manufacturer and service provider of advanced cell therapies,.
GERMANTOWN, Md., May 09, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a developer, manufacturer and service provider of advanced cell therapies, today.
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced it has received Institutional Review Board (IRB) approval to collect liver biopsies from patients at Rambam Medical Center located in Haifa, Israel for a planned study to confirm the suitability of liver cells for personalized cell replacement therapy for patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. The liver cells are intended to be bio-banked for potential future clinical use.
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of Orgenesis Inc. (NASDAQ:ORGS) have suffered share price declines over the last year. The share price is down a...
The Digital Issue of the Spring 2019 MicroCap Review Magazine,The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / SNN ...
Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that it has entered into an agreement with Columbia University, by which it will fund research to develop a cellular vaccination product platform, which it has licensed from Columbia University, for pancreatic, hepatic and cholangiocarcinoma cancers. Orgenesis will receive exclusive license on the technology developed at Columbia University under the research agreement. This patented and innovative dual-vaccine design utilizes whole cancer cells as a comprehensive source of antigens and the patient’s dendritic cells and macrophages to present the cancer antigens to the immune system.
GERMANTOWN, Md., April 11, 2019 -- Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that it has entered.
Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that it has entered into a collaboration agreement with Digilab Inc. to develop a live cell printing process and systems designed to automate the production of three-dimensional live cellular structures and tissues. Under the Agreement, Orgenesis will have the exclusive rights to co-develop the process and systems required for its therapeutic collaboration programs and to utilize, market and distribute the new cell printer systems and related products. The systems will incorporate Digilab’s proprietary synQUAD liquid dispensing technology, offering both on-the-fly and drop-by-drop, non-contact, cell printing, while maintaining the viability of even the most delicate cells.
Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced the publication of an independent study, entitled “The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells,” which was published in the February 2019 issue of Journal of Stem Cell Research and Therapy, a leading peer-reviewed journal in the field of stem cell therapy. Insulin dependent diabetes is a multifactorial disorder that could be theoretically cured by functional pancreatic islets and autologous insulin producing cells (AIP cells) implantation.
The JV will implement Orgenesis’ point-of-care (“POCare”) cell therapy strategy with a goal to bring Advanced Therapy Medicinal Products (ATMPs) to patients at the therapeutic setting by leveraging Orgenesis’ and TheraCell’s combined technical, regulatory and commercial expertise in Greece, Cyprus, Balkan region and Turkey. Under the Master Service Agreement, Orgenesis will provide regulatory consultancy services, pre-clinical studies, intellectual property (IP) services including IP life cycle management, and POCare services including training and technical runs, quality management systems and operational support.
LOS ANGELES, CA / ACCESSWIRE / March 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), ...
The new commercial facility is expected to be operational early in 2021 and is expected to triple Masthercell Global’s current capacity. The facility will include industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide cell and gene therapy customers an efficient and cost-effective manufacturing solution. Once the new commercial facility is operational, the current facility, also located within the Gosselies Biopark, will instead focus on industrial manufacturing process development and early to mid-stage, clinically-focused cell and gene therapy products.
In 2013 Vered Caplan was appointed CEO of Orgenesis Inc. (NASDAQ:ORGS). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider theRead More...
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today reported financial results and provided a business update for the fiscal year ended November 30, 2018.
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, will participate in a panel, “New Treatments for Diabetes and Obesity: Innovations for Chronic Diseases,” at the 2019 BIO CEO & Investor Conference. The panel will be held on Tuesday, February 12th, 2019 at 9:00 AM, Eastern Time, at the New York Marriott Marquis. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that Orgenesis’ Chief Scientific Officer, Sara Ferber Ph.D. will present the Company's novel and proprietary autologous trans-differentiation cell therapy technologies for the treatment of diabetes at The International Research Training Group (IRTG) 2251 "Immunological and Cellular Strategies in Metabolic Disease" (ICSMD) retreat which is being held on February 4-7th, 2019 at King’s College London.
Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced the opening of new offices and laboratories at Accessia Pharma in Liège, Belgium for its Belgian subsidiary, Orgenesis SPRL, in order to support its Point of Care (“POCare”) Cellular Therapy platform. Orgenesis is supported by its partners: Theracell (Greece), Hemogenyx (UK), Serpin (USA), to further expand cellular therapy development in the Walloon Region of Belgium.
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that its subsidiary, Masthercell Global Inc. (“Masthercell Global”), is expanding into the United States and has executed a lease agreement to build a new 30,000 sq. ft manufacturing facility in Houston, Texas. The new facility will allow Masthercell Global to expand its world presence and current capacities. Masthercell Global is a leading cell and gene therapy Contract Development and Manufacturing Organization (“CDMO”) that will now have operations and manufacturing facilities across three continents (North America, Europe and Asia).
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, from Atvio Biotech Ltd. management, which is wholly-owned by Orgenesis’ Masthercell Global subsidiary, will be presenting at the Phacilitate Leaders World 2019 Conference. The presentation will be held on Thursday, January 24, 2019 at 3:50 p.m. Eastern Standard Time at the Hyatt Regency Miami. The presentation is entitled, "Bringing cell therapy to the point of care, automation, analytics and everything between.” The Company will also host a booth (#804) throughout the duration of the event.
Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, has been selected to participate in a workshop entitled “Cell and gene therapy: The financing surge” at the 2019 Biotech Showcase. Vered Caplan has been invited to discuss how disruptive therapeutic products have shifted the investment and financial landscape within the Gene and Cell Therapy sector. Orgenesis is a vertically integrated developer, manufacturer and service provider in the cell and gene therapy industry.
NEW YORK, Dec. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.